Logo image of AKTS

AKTIS ONCOLOGY INC (AKTS) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:AKTS - US00973N1028 - Common Stock

20.56 USD
-0.25 (-1.2%)
Last: 1/15/2026, 8:00:00 PM
20.6 USD
+0.04 (+0.19%)
After Hours: 1/15/2026, 8:00:00 PM

AKTS Key Statistics, Chart & Performance

Key Statistics
Market Cap3.18B
Revenue(TTM)29.41M
Net Income(TTM)-154.24M
Shares154.59M
Float149.46M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.42
PEN/A
Fwd PEN/A
Earnings (Next)02-11
IPO2017-03-13
Sector
GICS IndustryElectronic Equipment, Instruments & Components
GICS IndustryGroupTechnology Hardware & Equipment
GICS SubIndustryElectronic Components
AKTS short term performance overview.The bars show the price performance of AKTS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months

AKTS long term performance overview.The bars show the price performance of AKTS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of AKTS is 20.56 USD.

AKTIS ONCOLOGY INC / AKTS Daily stock chart

AKTS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to AKTS.


Chartmill TA Rating
Chartmill Setup Rating

AKTS Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AKTS. Both the profitability and financial health of AKTS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AKTS Financial Highlights

Over the last trailing twelve months AKTS reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -49.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -268.85%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%85%
Sales Q2Q%28.92%
EPS 1Y (TTM)-49.48%
Revenue 1Y (TTM)2.97%

AKTS Forecast & Estimates

7 analysts have analysed AKTS and the average price target is 0.26 USD. This implies a price decrease of -98.76% is expected in the next year compared to the current price of 20.56.

For the next year, analysts expect an EPS growth of 42.58% and a revenue growth 29.7% for AKTS


Analysts
Analysts45.71
Price Target0.26 (-98.74%)
EPS Next Y42.58%
Revenue Next Year29.7%

AKTS Ownership

Ownership
Inst Owners14.98%
Ins Owners2.52%
Short Float %N/A
Short RatioN/A

About AKTS

Company Profile

AKTS logo image Akoustis Technologies, Inc. is a filter solutions company, which engages in the development, design, and manufacture of radio frequency (RF) filter products. The company is headquartered in Huntersville, North Carolina and currently employs 117 full-time employees. The company went IPO on 2017-03-13. The firm has developed a microelectromechanical system (MEMS) based BAW technology and a manufacturing process flow, called XBAW, for its filters produced for use in RF front-end modules. Its XBAW filters incorporate optimized high purity piezoelectric materials for high power, high frequency and wide bandwidth operation. The company is developing RF Filters for 5G, Wi-Fi and defense bands using its resonator device models and product design kits. The firm provides solutions for the wireless industry, including for products such as smartphones and tablets, network infrastructure equipment, Wi-Fi Customer Premise Equipment, and defense applications. Its segments include Fabrication Services and RF Filters. Fabrication Services segment consists of engineering review services and backend packaging services. RF Filters segment consists of amplifier and filter product sales.

Company Info

AKTIS ONCOLOGY INC

9805 Northcross Center Ct Ste A

Huntersville NORTH CAROLINA 28078 US

CEO: Jeffrey B. Shealy

Employees: 222

AKTS Company Website

AKTS Investor Relations

Phone: 17026054086

AKTIS ONCOLOGY INC / AKTS FAQ

What does AKTIS ONCOLOGY INC do?

Akoustis Technologies, Inc. is a filter solutions company, which engages in the development, design, and manufacture of radio frequency (RF) filter products. The company is headquartered in Huntersville, North Carolina and currently employs 117 full-time employees. The company went IPO on 2017-03-13. The firm has developed a microelectromechanical system (MEMS) based BAW technology and a manufacturing process flow, called XBAW, for its filters produced for use in RF front-end modules. Its XBAW filters incorporate optimized high purity piezoelectric materials for high power, high frequency and wide bandwidth operation. The company is developing RF Filters for 5G, Wi-Fi and defense bands using its resonator device models and product design kits. The firm provides solutions for the wireless industry, including for products such as smartphones and tablets, network infrastructure equipment, Wi-Fi Customer Premise Equipment, and defense applications. Its segments include Fabrication Services and RF Filters. Fabrication Services segment consists of engineering review services and backend packaging services. RF Filters segment consists of amplifier and filter product sales.


What is the current price of AKTS stock?

The current stock price of AKTS is 20.56 USD. The price decreased by -1.2% in the last trading session.


Does AKTIS ONCOLOGY INC pay dividends?

AKTS does not pay a dividend.


How is the ChartMill rating for AKTIS ONCOLOGY INC?

AKTS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Where is AKTIS ONCOLOGY INC (AKTS) stock traded?

AKTS stock is listed on the Nasdaq exchange.


What do analysts say about AKTIS ONCOLOGY INC (AKTS) stock?

7 analysts have analysed AKTS and the average price target is 0.26 USD. This implies a price decrease of -98.76% is expected in the next year compared to the current price of 20.56.


What is the employee count for AKTS stock?

AKTIS ONCOLOGY INC (AKTS) currently has 222 employees.